EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business Update
BOSTON, Nov. 16, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today reported financial results for the third quarter of 2015, and provided a business update.
“This is an exciting time for EPIRUS as we bring monoclonal antibody biosimilars to patients worldwide and execute our global strategy of building a robust biosimilar business,” stated Amit Munshi, president and chief executive officer, EPIRUS Biopharmaceuticals. "We enhanced our global commercialization capabilities, expanded our biosimilar pipeline and in-house product development capabilities, gained important patient exposure, filed in several additional early launch markets, presented BOW015 data at recent European League Against Rheumatism and American College of Rheumatology meetings, and achieved readiness for the start of the pivotal global Phase 3 clinical study for BOW015. We believe that the combination of the previously completed BOW015 Phase 1 and Phase 3 studies, the global patients treated from early launch markets, and the pivotal Phase 3, should it be successful, form the foundation for a strong global regulatory package for BOW015.”
Hey, check out all the research scientist jobs. Post your resume today!
“This is an exciting time for EPIRUS as we bring monoclonal antibody biosimilars to patients worldwide and execute our global strategy of building a robust biosimilar business,” stated Amit Munshi, president and chief executive officer, EPIRUS Biopharmaceuticals. "We enhanced our global commercialization capabilities, expanded our biosimilar pipeline and in-house product development capabilities, gained important patient exposure, filed in several additional early launch markets, presented BOW015 data at recent European League Against Rheumatism and American College of Rheumatology meetings, and achieved readiness for the start of the pivotal global Phase 3 clinical study for BOW015. We believe that the combination of the previously completed BOW015 Phase 1 and Phase 3 studies, the global patients treated from early launch markets, and the pivotal Phase 3, should it be successful, form the foundation for a strong global regulatory package for BOW015.”
Hey, check out all the research scientist jobs. Post your resume today!